CNR1 and post-traumatic stress disorder: In sum, existing work provides support for the notion that underlying differences in endocannabinoid signaling in PTSD may result in altered sensitivity or dose response shifts to CB1 agonists, resulting in differential responses to cannabis compared to psychiatrically healthy controls.